August 10, 2025 a 07:31 am

ALB: Dividend Analysis - Albemarle Corporation

Albemarle Corporation Logo

Albemarle Corporation, a diversified specialty chemicals manufacturing company, has solidified its position with a consistent dividend history spanning 32 years. Despite challenges reflected by negative payout ratios and fluctuating profitability metrics, the company maintains an admirable dividend yield of 2.15%. Investors should be cautious about the company's dividend growth, which shows moderate increment over the past years.

๐Ÿ“Š Overview

Metric Value
Sector Chemicals
Dividend yield 2.15%
Current dividend per share $2.65
Dividend history 32 years
Last cut or suspension None

๐Ÿ—ฃ๏ธ Dividend History

The consistency in Albion's dividend history, spanning over three decades, indicates an established payout strategy. This is a testament to their commitment to returning value to shareholders, despite recent financial strains.

Dividend History Chart
Year Dividend per Share (USD)
2025 $1.215
2024 $1.610
2023 $1.600
2022 $1.580
2021 $1.560

๐Ÿ“ˆ Dividend Growth

Albemarle's modest dividend growth of 1.83% over the past 5 years reflects a cautious reiteration of shareholder value, signaling internal reinvestment strategies or market adaptation efforts.

Time Growth
3 years 1.06%
5 years 1.84%

The average dividend growth is 1.84% over 5 years. This shows moderate but steady dividend growth.

Dividend Growth Chart

โš ๏ธ Payout Ratio

Payout ratios provide insights into Albemarle's financial strategies. Current negative values suggest financial pressures, as the EPS-based payout ratio is -33.52%, and the FCF-based stands at a challenging -568.07%. This highlights discrepancies between profitability and cash flow allocation.

Key figure Ratio
EPS-based -33.52%
Free cash flow-based -568.07%

๐Ÿ’ฐ Cashflow & Capital Efficiency

The following metrics underscore Albemarle's cash flow health and capital deployment efficiencies. Assessing these is crucial as they highlight potential operational challenges and strategic capital allocations.

Metric 2022 2023 2024
Free Cash Flow Yield 2.54% -4.86% -9.72%
Earnings Yield 8.04% 9.28% -11.66%
CAPEX to Operating Cash Flow 66.13% 162.17% 240.11%
Stock-based Compensation to Revenue 0.42% 0.38% 0.60%
Free Cash Flow / Operating Cash Flow Ratio 33.87% -62.17% -140.11%

These challenges in free cash flow yield and high CAPEX ratios indicate a potential strain on near-term liquidity.

๐Ÿ“‰ Balance Sheet & Leverage Analysis

Analyzing these leverage and liquidity metrics helps investors gauge Albemarle's ability to meet its financial obligations and sustainably manage debt.

Metric 2022 2023 2024
Debt-to-Equity 40.30% 45.80% 36.30%
Debt-to-Assets 20.81% 23.60% 21.77%
Net Debt to EBITDA 0.60 4.32 -2.40
Current Ratio 1.89 1.47 1.95
Quick Ratio 1.13 0.86 1.19
Financial Leverage 1.94 1.94 1.67

The stabilization in debt levels and improvements in liquidity ratios are reassuring, but the negative net debt-to-EBITDA in 2024 requires close monitoring.

โœ… Fundamental Strength & Profitability

The following metrics provide insight into Albemarle's fundamental performance, analyzing profitability and efficiency in capital utilization.

Metric 2022 2023 2024
Return on Equity 25.59% 16.71% -11.84%
Return on Assets 13.22% 8.61% -7.10%
Net Margin 27.91% 16.36% -21.93%
EBIT Margin 34.92% 3.77% -29.72%
Research & Development to Revenue 0.98% 0.89% 1.61%

The profitability metrics show variance, highlighting periodic challenges, yet showcase investment in R&D that could fuel future growth.

๐Ÿ“‰ Price Development

Stock Price Chart

โœ… Dividend Scoring System

Category Score Visual
Dividend yield 3
Dividend Stability 4
Dividend Growth 2
Payout Ratio 1
Financial Stability 2
Dividend Continuity 5
Cashflow Coverage 1
Balance Sheet Quality 3
Total Score: 21/40

๐Ÿ—ฃ๏ธ Rating

Albemarle Corporation holds a resilient dividend background with a commitment to shareholder returns. While facing financial obstacles highlighted by negative payout ratios and profitability challenges, the strong continuity of dividends and strategic R&D investments suggest potential for long-term growth. Cautious optimism is recommended for investors, pending further improvements in financial metrics.